Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Daratumumab with GDP in Relapsed/Refractory PTCL
NCT04251065Phase 2Terminated
- Sponsor
- Fondazione Italiana Linfomi
- Start
- Sep 2020
- Primary completion
- Dec 2021
- Modality
- Recombinant Proteins and Enzymes, Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 2 trial of daratumumab in peripheral T-cell lymphoma not otherwise specified (PTCL-NOS), angioimmunoblastic T-cell lymphoma (AITL), nodal T-follicular helper cell lymphoma (T-FHCL), sponsored by Fondazione Italiana Linfomi. Started Sep 2020; status: terminated.
02
Drugs
daratumumab
03
Conditions
peripheral T-cell lymphoma not otherwise specified (PTCL-NOS)angioimmunoblastic T-cell lymphoma (AITL)nodal T-follicular helper cell lymphoma (T-FHCL)
Beyond the preview
Go deeper on NCT04251065.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04251065.